Johnson & Johnson's apalutamide plus hormone therapy reduces metastasis risk in Phase III prostate cancer trial

Johnson & Johnson reported Phase III data on Saturday showing that apalutamide (Erleada) added to hormone therapy before and after localized prostate cancer surgery reduced the risk of metastasis or death by 20% compared with hormone therapy alone — results that, if they translate into regulatory approval, would mark the first time an androgen receptor inhibitor has been sanctioned for perioperative use in this curative-intent setting.

The PROTEUS trial is a randomized, double-blind, placebo-controlled Phase III study that enrolled 2,109 patients with newly diagnosed high-risk localised or locally advanced prostate cancer who were candidates for radical prostatectomy. Patients received apalutamide 240 mg orally once daily plus androgen deprivation therapy (ADT), or placebo plus ADT, for six months before and after surgery — approximately one year of total systemic treatment. The study carried dual primary endpoints: pathologic complete response or minimal residual disease (pCR/MRD) at surgery, and metastasis-free survival (MFS), both assessed by blinded independent central review.

At a median follow-up of 61.7 months, both endpoints were met. The pCR/MRD rate was 8.9% with apalutamide plus ADT versus 1.0% with ADT alone (odds ratio 10.17; 95% CI 5.27–19.64; p < 0.0001), meaning patients in the combination arm were roughly nine times more likely to have little or no cancer remaining at the time of surgery. On MFS, the combination produced a statistically significant 20% reduction in the risk of metastasis or death (HR 0.80; 95% CI 0.67–0.96; p=0.02), with five-year MFS rates of 78.2% versus 73.5%. Among secondary endpoints, the time before patients required subsequent therapy extended to more than six years with apalutamide plus ADT compared with approximately 3.5 years with ADT alone (74.2 vs. 41.5 months; HR 0.65; p < 0.0001), and event-free survival improved by 29% (HR 0.71; p < 0.0001).

The safety profile was consistent with prior apalutamide studies. Grade 3 or 4 adverse events occurred in 39.6% of patients on the combination versus 31.0% on ADT alone, and discontinuations due to adverse events were 7.4% versus 2.7%, respectively. Death rates were similar between arms, though deaths in the apalutamide group were more often unrelated to prostate cancer, while deaths in the placebo group were more frequently associated with disease progression. Most patients recovered adequate testosterone levels within a median of 8.1 months following treatment completion. The data were presented in a plenary session at the 2026 ASCO Annual Meeting and simultaneously published in the New England Journal of Medicine.

Competitive context

The PROTEUS readout arrives in a prostate cancer landscape where second-generation androgen receptor inhibitors — including Pfizer and Astellas' Xtandi (enzalutamide) and Bayer's Nubeqa (darolutamide) — have reshaped treatment across non-metastatic and metastatic castration-sensitive and castration-resistant settings, but none holds approval for the perioperative curative-intent space. The current standard of care for patients with high-risk localized prostate cancer undergoing radical prostatectomy remains ADT as a systemic backbone, without an approved AR inhibitor component. Apalutamide is already approved for non-metastatic castration-resistant and metastatic hormone-sensitive prostate cancer, and the PROTEUS data extend its clinical footprint into an earlier disease stage where, as the trial illustrates, nearly half of patients who undergo surgery alone will experience disease recurrence.

The 20% reduction in metastasis or death is a modest but statistically robust signal in a population where the comparator arm itself includes active hormone therapy — not surgery alone. Cross-trial comparisons are limited, but the magnitude of MFS benefit is broadly consistent with what second-generation AR inhibitors have demonstrated in non-metastatic castration-resistant settings, where enzalutamide and darolutamide produced more pronounced MFS hazard ratios in populations that had already progressed on ADT. The perioperative context is distinct: patients here are castration-naive, and the addition of deeper AR blockade during a window of micrometastatic vulnerability around surgery represents a mechanistically different intervention than post-progression intensification. Apalutamide functions as a selective androgen receptor inhibitor, blocking AR nuclear translocation and DNA binding on top of castration-level testosterone suppression — targeting residual AR signalling that persists even under effective ADT.

One comparator worth noting in the radiotherapy context is Johnson & Johnson's own Zytiga (abiraterone acetate), which holds EMA approval in combination with ADT and radiotherapy for locally advanced prostate cancer based on STAMPEDE trial data, though its FDA label in this specific localised-plus-radiotherapy setting is less clearly defined. Apalutamide, unlike abiraterone, does not require mandatory corticosteroid co-administration, which simplifies the perioperative regimen. An ongoing Phase III study, ATLAS, is separately evaluating apalutamide in combination with radiotherapy in high-risk localised or locally advanced prostate cancer — a dataset that, if positive, would further extend the molecule's reach in non-surgical curative-intent management.

Apalutamide plus ADT has not yet received regulatory approval in the perioperative setting. Johnson & Johnson has not disclosed a filing timeline, though the PROTEUS final analysis and simultaneous NEJM publication position the package for near-term submission. Additional analyses comparing the perioperative combination against surgery alone are described as ongoing, which may be relevant to regulators seeking to contextualize the benefit against the broadest definition of current practice. A regulatory decision in this setting would represent the first approval of any AR inhibitor for localized prostate cancer surgery — a meaningful shift in how a disease that affects an estimated 15% of newly diagnosed patients at high-risk presentation is managed from the point of curative intent.

---

Spot something wrong? Report an issue with this article